Tag: research

LUXEMBOURG , Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift, a blockchain protocol combining Proof-of-Work (PoW), Proof-of-Stake (PoS), and an AI-powered Proof-of-Yield (PoY) mechanism, has officially entered Stage 3 of its presale. The platform is offering tokens at $3 during this limited 64-day window, with a scheduled increase to $4 in the next stage and a confirmed launch price of $15.

SINGAPORE, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ostium, a decentralized trading platform, has announced the launch of a new leveraged trading instrument: 0DTE perpetuals for equities. The instrument combines intraday expiry with perpetual structure, offering day traders up to 100x leverage on individual stocks during market hours — a structural innovation aimed at addressing the limitations of traditional options and CFDs.

ROAD TOWN, British Virgin Islands, Aug. 01, 2025 (GLOBE NEWSWIRE) -- OZAK AI has made a significant impact in the crypto and AI investment sector. It is capturing serious attention after completing its Certik audit (considered to be the best benchmark of security in blockchain projects worldwide) and raising over $1.5 million, with its presale ongoing, at just $0.005 per token.

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), have until September 26, 2025 to seek appointment as lead plaintiff of the Lockheed Martin class action lawsuit. Captioned Khan v. Lockheed Martin Corporation, No. 25-cv-06197 (S.D.N.Y.), the Lockheed Martin class action lawsuit charges Lockheed Martin and certain of Lockheed Martin’s top current and former executives with violations of the Securities Exchange Act of 1934.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.